New Novartis financial reports reflect restructuring

1 April 2016
drugs_pills_tablets_big

Swiss pharma giant Novartis (NOVN: VX) has published updated 2015 segment financials taking into account the major restructuring which was announced in January.

Part of this restructuring was the company’s ophthalmic franchise moving from its underperforming ophthalmic Alcon division to its pharmaceuticals arm.

A portfolio of 19 mature products transferred from the pharmaceuticals unit to the Sandoz division, meanwhile.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics